Abstract
The University of California has accepted an offer of $200 million from South San Francisco-based biotech giant Genentech to settle a potentially costly patent-infringement lawsuit. The university originally sued Genentech in 1990, claiming the company illegally used UC-patented human growth hormone DNA information in developing Genentech's highly successful growth drug Protropin. The drug is used to treat growth hormone deficiency in children. During a high-profile trial that began last April, a jury was told that on New Year's Eve 1978, Peter H. Seeburg, then a researcher at Genentech, stole the genetic material from his old lab at the University of California, San Francisco (UCSF). The suit alleged that Genentech then used the material in such a way as to infringe on UC's patent. A jury voted 8 to 1 in favor of the university last June, falling just short of the unanimous verdict required for a conviction. Facing a potentially lengthy and expensive retrial that ...
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
